1 / 19

Regional Update

Regional Update. Financial Report. Governance Report. Dr. Joel Pachter Progressive MS Update. Leukocytes enter the CNS during neuroinflammation. The blood-brain barrier is damaged during EAE/MS. Urgent Need to Find Solutions for People with Progressive MS.

brooke-simon
Download Presentation

Regional Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Regional Update

  2. Financial Report

  3. Governance Report

  4. Dr. Joel Pachter Progressive MS Update

  5. Leukocytes enter the CNS during neuroinflammation

  6. The blood-brain barrier is damaged during EAE/MS

  7. Urgent Need to Find Solutions for People with Progressive MS • Large worldwide impact: about half of all MS patients • Finding solutions for progressive MS is one of the top priorities for patients • Currently paucity of effective DMT for progressive forms of MS • Every time another therapy is approved for RRMS, a large proportion of our constituents feel left behind

  8. Society Research Priorities To better understand the biological basis for disease progression To dissect the mechanisms of nerve damage and repair To identify risk and triggering factors for MS To enable development of new or improved rehabilitation techniques To grow the global MS research enterprise $46 million in current commitments to progressive MS research

  9. Progressive MS Research Initiatives • Over 100 investigator initiated research projects • MS Outcomes Assessment Consortium • Clinical Trials- MS SMART, SPRINT MS • SUMMIT natural history and risk factors study • Revision of Lublin-Reingold Clinical Course Descriptor • International Progressive MS Alliance

  10. Mission To expedite the development of effective disease modifying and symptom management therapies for progressive forms of multiple sclerosis

  11. Better extravasating of hES-MSC

  12. Where is MS research going? • Novel drugs that act on “special” targets (e.g., CCL2) Riluzole – sodium channel blocker Amiloride – diuretic/neuroprotective Ibudilast – anti-inlfammatory/neuroprotective • Stem cell therapy with multifunctional “reparative” rather • “replacement” cells

  13. Q&AMedications & Treatments • What FDA approved medications can we expect for secondary progressive MS, and when? • When will oral therapies be available for progressive MS? • I see your major research interests are blood brain barrier & neuroinflammation. How do you feel about these as treatment options? What do you suggest we look for when searching for a doctor to treat this?

  14. Q&AStem Cells • How soon are we going to see expansion of the stem cell clinical trials? • Are clinical trails for stem cells taking place in the US? • Will stem cell therapy become available and if so how would this therapy help any type of MS?

  15. Q&ARestoring Function • What are the prospects for remylination? • What progress has been made in RESTORING function, especially in patients who've had MS 20 years?

  16. Q&AGeneral • What is the difference between the different types of MS? My daughter was recently diagnosed. • As an undergraduate student starting to study MS, where is the best place to start? • Will there ever be a cure for MS? • Is it common for Parkinsons Disease and MS to occur in the same person? Is research being done around this?

More Related